HIGHLIGHTS
- who: Xue Lu from the Brisbane, QLD, Australia have published the article: CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors, in the Journal: (JOURNAL)
- what: The authors aimed to develop a novel combination therapy by targeting SSRP1 using a small molecule inhibitor with PARPi in HR-proficient HGSCs. The authors show that SSRP1 inhibition using a small molecule that traps SSRP1 onto chromatin exerts a significant anti-growth activity in vitro against HGSC cell lines and patient-derived tumor cells and also reduces tumor burden in vivo. induced . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.